230 related articles for article (PubMed ID: 22342565)
21. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
22. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
[TBL] [Abstract][Full Text] [Related]
23. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
24. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
25. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.
van der Sandt IC; Smolders R; Nabulsi L; Zuideveld KP; de Boer AG; Breimer DD
Eur J Pharm Sci; 2001 Aug; 14(1):81-6. PubMed ID: 11457654
[TBL] [Abstract][Full Text] [Related]
26. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
27. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
28. Similarities and differences in the localization, trafficking, and function of P-glycoprotein in MDR1-EGFP-transduced rat versus human brain capillary endothelial cell lines.
Gericke B; Borsdorf S; Wienböker I; Noack A; Noack S; Löscher W
Fluids Barriers CNS; 2021 Aug; 18(1):36. PubMed ID: 34344390
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
30. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
Kuteykin-Teplyakov K; Luna-Tortós C; Ambroziak K; Löscher W
Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
[TBL] [Abstract][Full Text] [Related]
32. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
33. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
[TBL] [Abstract][Full Text] [Related]
34. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier.
Sugiyama D; Kusuhara H; Lee YJ; Sugiyama Y
Pharm Res; 2003 Sep; 20(9):1394-400. PubMed ID: 14567633
[TBL] [Abstract][Full Text] [Related]
35. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
36. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.
Löscher W; Luna-Tortós C; Römermann K; Fedrowitz M
Curr Pharm Des; 2011; 17(26):2808-28. PubMed ID: 21827408
[TBL] [Abstract][Full Text] [Related]
37. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
[TBL] [Abstract][Full Text] [Related]
38. The putative proton-coupled organic cation antiporter is involved in uptake of triptans into human brain capillary endothelial cells.
Svane N; Pedersen ABV; Rodenberg A; Ozgür B; Saaby L; Bundgaard C; Kristensen M; Tfelt-Hansen P; Brodin B
Fluids Barriers CNS; 2024 May; 21(1):39. PubMed ID: 38711118
[TBL] [Abstract][Full Text] [Related]
39. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
[TBL] [Abstract][Full Text] [Related]
40. Is aspirin a substrate of MDR1/P-glycoprotein?
Singh R; Naik T; Nigam A; Chatterjee S; Rajanna P; Shen H; Iyer R
Xenobiotica; 2020 Oct; 50(10):1258-1264. PubMed ID: 32302241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
